Earnings Call · Q2 FY2021·2021-08-09

Q2 21EPS +15.38%·Rev n/aQ1 21EPS +5.80%·Rev n/aQ4 20EPS -100.00%*·Rev n/aQ3 20EPS -17.78%·Rev n/a⚠ consensus missing

ROCKET PHARMACEUTICALS, INC. RCKT

Mayur Kasetty — Director of Business Development and Operations and Investor Relations lead

Gaurav Shah — Chief Executive Officer

Claudine Prowse — Employee / Executive (exact role not specified)

−1.8%1d on move date−1.9% vs SPY3d−8.4%5d−10.8%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more RCKT calls or request research access.

More RCKT calls Browse calls Request research access